Answer
Exposure to both components can increase with renal or hepatic impairment. The selected product is contraindicated in moderate or severe hepatic impairment, while renal impairment and mild hepatic impairment require caution and clinical monitoring.
Sources for this answer
- Targinact 5 mg/2.5 mg prolonged-release tabletsemc · SmPC Current selected SmPC · Version 8